Beta features

Activate the beta mode on your Inpart Deal platform to try new features and send feedback before their official release.

- Feature #1: Opportunity page new layout
- Feature #2: One-pager reports

October 9, 2024



What are beta features?

Beta features are early-access versions of new features and improvements that the Inpart Product team is currently working on for Inpart Deal.

By trying them before their official release, you get a firsthand look at what's coming next. It's a great way to explore new functionalities, while your feedback helps us refine and perfect these features.

Together, we can shape a better product that meets your needs.

How does it work?

Contact your Customer Success Manager at Inpart to enable the beta mode on your Deal environment.

Important:

- The beta mode can only be enabled for all the users at the same time, so make sure to communicate it to your team.
- Enabling or disabling the beta mode has no impact on the data you enter on the platform.

Opportunity page new layout

We're excited to announce a redesign of the opportunity page! This update will help you stay more productive and focused, ensuring that important details are always up-to-date and readily accessible.

Key improvements include:

- **Reduced number of tabs:** We've reorganized tabs so that all available information is always visible, in panel view or full page view, without having to scroll.
- **Improved information grouping:** Information is now more logically grouped, making it easier to find and update key details without navigating multiple tabs.
- **Task and evaluation panel:** To ensure tasks can be created anytime while working on your opportunities, they can now be opened as a panel from the top menu.
- Action cards: Four action cards have been added to the *Overview* tab to give you the latest updates on your meetings, comments, tasks and evaluations.



Larger Workspace

The static elements on the right-side of the page were moved to free space for more actionable information.

1 The CDAs, the Connect Campaign and the Due Diligence Module integrations have been moved to the *Overview* tab.

Tags have been moved to the *Details* tab.

AFTER

BEFORE

← Back						MS 🔕 👶 View access 💠	
DAE-123 Status Active	Owned by M6 Melissa Scott	Company	Agreements None			CDA © Active Effective date Mon, Sep 30, 2024 Sat, Sep	View ^
dentification Aug 2, 2024	O Screening Aug 29, 2024	• To be defined	•			Due Diligence	^
Overview Asset Deta Status update	ails Summary Attachmen	ts 0 Tasks 2 Meetings	O Contacts O Agreen	nents 0		1, Inpart Connect Connection request	^
Add updates and nex					~	Connection status Not requested Submission type spinout	t connection
Related compa	anies			+ Add	~	Tags Tags	2 ^
Related oppor	tunities 💿			+ Add	~	BIO2022 I Research Proj. I Technolo	gy 💿 Search for 🗸 🗸

ABC-26723										
O Active V	MS Melissa Scott	ABC Pharma CDA + 1								
		0								
Identification Jan 2, 2024	Screening Jan 3, 2024	Confidential Evaluation Jul 19, 2024 View instructions	Due Diligence	Negotiation	Contracti	ng Sig	ned			
Overview Details M	eetings 0 Contacts 3 Attac	hments 3 Related information								
0 meetings in last 3	0 days	G 3 comments in last 30 days		1 ongoing evaluation		✓ 3 open tasks				
Status update	9, 2024 by MS Melissa Scott		+ Add new E	CDA O Active			View ^			
Updates				Effective date Wed, Sep 25, 2024		Expiration date Mon, Sep 24, 2029				
Cross-functiona	al meeting with company to be scher	duled if feedback is positive.		Due Diligence						
Next steps				Send to Due Diligence	e					
Check on data a	vailability to pursue further.			t Inpart Connect	equest		^			
Notes Last updated 2 weeks	Overview Details Meeting	gs 0 Contacts 3 Attachm	nents 3 Related	information						
	Orphan Drug 💿 Out-licens	sing 💿 Search for tags						2		
	Pharma asset			🖉 Edit 🗸 🗸	Opportunity mar	nagement			^e Edit	
	Scientific classific	ation		🖉 Edit 🗸 🗸	Financial informa	ation		1	' Edit	

One single Information Tab

All information fields were grouped under the *Details* tab to ease the navigation

The Opportunity overview section was moved to the Details tab and renamed General information.

All fields in the *Asset* tab were moved the *Details* tab.

Tags can now be found at the top of the *Details* tab.

AFTER

		and the second secon			
← Back		← Back			& View access
∂ DAE-123		ABC-26723			
Status Owined by Company Agreements O Active Millisea Scott III Deejeon Biometrics None		Active Melissa Scott ABC Pharma	CDA Licensing		
Concerning To be defined Aug 2, 2024 Aug 29, 2024		Kenetification Screening Jan 2, 2024 Jan 3, 2024	Confidential Evaluation Due Dilligence Jul 19, 2024 Wew Instructions	• Negotiation	Contracting Signed
		Overview Details Attachments (3) Meetings (2) Contacts (3) Related in	nformation		
Overview Asset Details Summary Attachments 0 Tasks 2 Meetings 0 Contacts 0 Agreements 0		Search for Laga		1	
Status update Add updates and next steps		Pharma asset	∠ Edit v	Opportunity management	
		Scientific classification	2 / tat ~	Financials	
Opportunity overview V		Pharma assessment	Edπ ∨	Intellectual Property	
Related companies 0 + Add v		Territories	🖉 Edit) 🗸 🗸	General information	
Related opportunities 0 Overview Asset Details Summary Attachments 11 T	asks 0 Meetings 0 Contacts 0 Agreements 1			General	Asset type
				Opportunity type	À Pharma asset
Pharma asset	2 Edit V			In-Licensing	
Scientific classification	Edit v			Discovery Discovered on Jan 2, 2024	Discovered by
				Source Conference	Source conference BIO Asia
Pharma assessment	Z Edit V			Source details -	

BEFORE

/ Edit

Practical **Overview**

The *Overview* tab now groups the most frequently used features and gives a quick outlook of the opportunity state

The *Status update* and the *Notes* (previously in the *Summary* tab) are now easily accessible in the *Overview* tab.

2) The CDA information, and the Due Diligence and Connect integrations are now quickly visible in the Overview tab.

Action cards tell at a glance if meetings recently happened, if comments were recently adedd, and if any evaluations or tasks are currently open.

		ABC-26723 Active Ms Mellssa Scott ABC Pharma CDA +1
ABC-55		
Status Owned by Company Agreements Active Ms Melissa Scott III APIC/PRU CDA	CDA O Active	Identification Screening Confidential Evaluati Due Diligence Negotiation Contracting Signed Jan 2, 2024 Jan 3, 2024 Jul 19, 2024 View Instructions
Identification Triage Confidential Eval Due Diligence Negotiation Contracting Closed	Effective date Expiration date Wed, Oct 9, 2024 Mon, Oct 8, 2029	
Mar 21, 2024 Mar 21, 2024 Mar 21, 2024	Due Diligence 2 ^	Overview Details Meetings 2 Contacts 3 Attachments 3 Related information
Overview Asset Details Summary ttachments 0 Tasks 8 Meetings 0 Contacts 0 Agreements 1	Due Diligence 2 Øsend to Due Diligence 1	🗎 2 meetings in last 30 days 💭 3 comments in last 30 days 🗊 1 ongoing evaluation 🖂 3 open tasks
Status update Add updates and next steps + Add	*s least Connect Connection request	Status update + Add new Last updated on Jul 19, 2024 by MS Mellissa Scott + Add new
Opportunity overview ~	Connection status Pending Cancel connection Submission type Blopharma Asset	Updates Effective date Expiration date Wed, Sep 25, 2024 Mon, Sep 24, 2029
Related companies		Cross-functional meeting with company to be scheduled if feedback is Due Diligence 2
Related opportunities 0 + Add v		Next steps @Send to Due Diligence
		Check on data availability to pursue further. Connection request
		Connection status Pending Cancel connection
		Notes Submission type Last updated 2 weeks ago by

BEFORE

Accessible **Tasks**

Create and manage your tasks and evaluations at anytime from the header

A task button was added to the header to open the new *Tasks and Evaluations* panel.

The avatars of the users with access to the opportunity were removed to save space and gain clarity. The full list of users is still available from the *View access* button.

ORE			AFTER
(*	Back	MS & & View access : B . CO	
(DAE-123 Active v Melissa Scott 2005 South 2	8 Ø % Q 2	DAE-123 Active Condition Screening Confident
	dentification Screening To be defined ug 2, 2024 Aug 29, 2024 Constant Constant	Due Diligence	Mar 7, 2023 Mar 13, 2023 Mar 13, 2023 Apr 6, 2023 Feb 16, 2024
		@Send to Due Dilligence	Overview Details Attachments 11) Meetings 0 Contacts 0 Related information
	verview Asset Details Summary Attachments 0 Tasks 2 Meetings 0 Contacts 0 Agreements 0	1s Inpart Connect Connection request	
	Status update Add updates and next steps	Connection status Not requested Request connection	
	Opportunity overview ~	Submission type spinout	
	Related companies 0 + Add v	Tags ^	
	Related opportunities 🕐 👘	1 BIO2022 () [Reserch Proj_ ()] Technology () Search for v	

BEFC

Visible **Tabs**

BEFORE

We reduced the number of tabs to ensure they were all visible at all times

The Related companies and Related opportunities sections were moved to the new Related information tab.

The Agreements tab was also merged into the Related information tab.

DAE-123 O Active None Identification Screening To be defined **DAE-123** Status Overview Asset Details Summary Attachments 0 Tasks 2 Meetings Screening Confidential Eval... Due Diligence Contracting Signed Identification Negotiation Status update Mar 7, 2023 Mar 13, 2023 Mar 13, 2023 Apr 5, 2023 Add updates and next steps . **Opportunity overview** eements </u> Tasks 2 Meetings 2 Contacts Agreements Related companies 0 Status Search **Related opportunities** Δ11 Se All ✓ III More filters 商 Title Status 🛧 Effective date Expiration date CDA with Mitsubishi Tanabe Pharma Corporati... Active Sep 30, 2024 Sep 29, 2029 Sep 29, 2029 CDA with Mitsubishi Tanabe Pharma Corporati... Sep 30, 2024 Active CDA with Mitsubishi Tanabe Pharma Corporati... CDA Sep 30, 2024 Sep 29, 2029 Active

AFTER ← Back & View access 8 % V Q 4 ABC-26723 Active Identification Confidential Evaluation Contracting Screening Due Diligence Negotiation Signed Overview Details Attachments 3 Meetings 2 Contacts 3 Related informatio Agreements 2 + Add 🗸 🗸 **Opportunities** + Add Companies + Add 🗸 🗸

Simpler **Header**

Subtitles were removed from the headline's details to gain space and clarity

The information remains the same, but the field titles are now displayed within tooltips when hovering over the information. As a reminder, the fields available are the opportunity status, the opportunity owner, the company evaluated in the opportunity, and the types of the agreements attached to the opportunity.

AFTFR

← Back			Si View access	- -
DAE-123				
Status Owned by Active Carter Control (12) Echo Zhang	Company Agreements		CDA O Active	View
	0		Effective date Mon. Sep 30, 2024	Expiration data Sat Sep 29, 2029
Status	Owned by	Company	4	Agreements
O Active 🗸	EZ Echo Zhang	🚊 Mitsubish	i Tanabe	CDA
Status update			Expired	_
Added on Sep 30, 2024 MS Melissa Scott		+ Add new :	Submission type Research Project	
Added on Sep 50, 2024 Mp. Meinssa Scott				
Updates			Tags	

DAE-123			
O Anthropad	CD4		
C Active V	Echo Zhang 🛄 Mitsubishi Tanabe CDA		
	Echo Zhang 📃 Mitsubishi Tanabe CDA		
	Echo Zhang Mitsubishi Tanabe CDA	ABC Pharma	CDA +1
		🔲 ABC Pharma	CDA +1
		🔲 ABC Pharma	Agreement type: Confidential
● Active ~	MS Melissa Scott	•	Agreement type: Confidential Disclosure Agreement, Licensing
			Agreement type: Confidential

One-pagers

Quickly export a one-page report from opportunities, designed for easy review during triage meetings and seamless sharing with stakeholders.

This update will enhance efficiency and ensure key insights are shared across your team effortlessly.



Deal plan


This feature offers a default template in the Deal Essential package, and custom templates in the Deal Advanced package.

How to use the feature

- Ž Help center article

Release plan

- 1. Oct 1, 2024: One-pager for opportunities
- 2. Oct 15, 2024: One-pager for companies
- 3. Oct 15, 2024: One-pager for meetings



Or inpart Thank you